Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
Author/Authors :
N Galie، نويسنده , , LJ Rubin، نويسنده , , MM Hoeper، نويسنده , , P Jansa، نويسنده , , H Al-Hiti، نويسنده , , GMB Meyer، نويسنده , , E Chiossi، نويسنده , , A Kusic-Pajic، نويسنده , , G Simonneau، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Pages :
8
From page :
2093
To page :
2100
Abstract :
Background
Treatments for pulmonary arterial hypertension have been mainly studied in patients with advanced disease (WHO functional class [FC] III and IV). This study was designed to assess the effect of the dual endothelin receptor antagonist bosentan i
